• MGMT promoter methylation prognostic biomarker for low-grade glioma

    7 days ago - By Healio

    O6-methylgaunine-DNA-methyltransferase, or MGMT, promoter methylation appeared to be significantly associated with PFS and OS among patients with high-risk low-grade glioma, according to findings from a correlative analysis of the NRG Oncology/Radiation Therapy Oncology Group 0424 clinical trial.
    This represented the first clinical trial-based evidence of the prognostic importance of MGMT promoter methylation among patients with grade 2 glioma.
    “also the first data to highlight the test's potential prognostic value beyond a standard molecular test currently used to help
    Read more ...